Gastric Cancer in China
Overview
Gastric (stomach) cancer is strongly linked to Helicobacter pylori infection and chronic gastritis. East Asian centers — including China’s — hold the world’s deepest experience in screening gastroscopy, endoscopic resection of early cancer and D2 radical surgery.
For early lesions, endoscopic submucosal dissection can cure the cancer while preserving the stomach; for advanced disease, perioperative chemotherapy and precision drug therapy follow international benchmarks.
Symptoms & Signs
Persistent indigestion or upper abdominal discomfort unrelieved by usual measures
Early fullness when eating and nausea
Black stools or anemia from chronic blood loss
Unexplained weight loss and loss of appetite
Vomiting, sometimes of blood, in advanced tumors
Early gastric cancer is usually silent and found on screening gastroscopy
Diagnosis
Gastroscopy with targeted biopsy — the definitive test
Endoscopic ultrasound assessing tumor depth for endoscopic resection planning
CT of chest, abdomen and pelvis for staging; PET-CT in selected cases
H. pylori testing with eradication therapy when positive
HER2, MSI and CLDN18.2 molecular profiling guiding advanced-disease therapy
Laparoscopy excluding peritoneal spread before surgery in locally advanced disease
Treatment Options
Endoscopic submucosal dissection (ESD) for early cancers meeting curative criteria — stomach-preserving
Laparoscopic or robotic gastrectomy with D2 lymphadenectomy for resectable disease
Perioperative (neoadjuvant plus adjuvant) chemotherapy for locally advanced cancer
HER2-targeted therapy, immunotherapy and second-line chemotherapy for advanced disease
Intraperitoneal chemotherapy for selected peritoneal involvement
Nutritional support and post-gastrectomy care programs
Advanced Technologies & Novel Drug
ESD and EFTR organ-preserving endoscopic resection platforms
ICG fluorescence-guided lymph node dissection during gastrectomy
Robotic and 3D-laparoscopic surgical systems
Fast-track recovery (ERAS) protocols
Novel CLDN18.2-targeted antibody therapy approved and available at Chinese cancer centers
Hospital & Specialist
- Cancer Hospital, Chinese Academy of Medical Sciences (CICAMS) — Beijing
- Zhongshan Hospital, Fudan University — Shanghai
- Sun Yat-sen University Cancer Center (SYSUCC) — Guangzhou
- West China Hospital, Sichuan University (Huaxi Hospital) — Chengdu
- Li Jun Ling — Medical Oncology
- Wang Xing Yuan — Medical Oncology
- Zhang Xiao Shi — Medical Oncology
- Lin Tong Yu — Medical Oncology